Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Genzyme, Isis solidify collaboration agreement
Genzyme and Isis Pharmaceuticals completed their agreement for the cholesterol drug candidate, mipomersen. The two companies have been developing an agreement to work together and announced earlier this year that the collaboration will grant Genzyme exclusive rights to the lipid-lowering drug that Isis has in development.
For the honor, Genzyme will pay Isis $175 million in licensing fees. Genzyme earlier paid $150 million for 5 million shares of the company's common stock. Isis will continue to contribute funding for the drug's development.
- see the release
- get the full story at the Boston Globe
- read about the deal at RTT News
Related Article:
Genzyme wins Isis pact with $1.9B bid
Cholesterol drug delay signals new FDA standards
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
